J Rheum Dis.  2023 Oct;30(4):211-219. 10.4078/jrd.2023.0037.

Epidemiology of systemic lupus erythematosus in Korea

• Han JY
• Cho SK
• Sung YK

• KMID: 2546237
• DOI: http://doi.org/10.4078/jrd.2023.0037

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse organ system disabilities, predominantly affecting young females. The clinical manifestations of SLE encompass various organs, including the kidney, cardiovascular system, and central nervous system. Young females with SLE experience higher mortality rates than the general population, making it imperative to gain insights into the disease patterns and associated factors. The current review examines the epidemiological studies to analyze the prevalence, incidence, and mortality trends of SLE in Korea and compares them with the findings from other countries. We aim to identify potential similarities, differences, and factors contributing to the burden of SLE in different populations by exploring the comparative epidemiological aspects. The knowledge derived from this comparison would aid in advancing the overall management of SLE in Korea.

Keyword

Systemic lupus erythematosus; Epidemiology; Mortality

Reference

1. Becker-Merok A, Nossent HC. 2006; Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 33:1570–7. PMID: 16845708.

2. Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. 2013; Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 12:444–54. DOI: 10.1016/j.autrev.2012.08.019. PMID: 23000206.

3. Li Z, Xu D, Wang Z, Wang Y, Zhang S, Li M, et al. 2017; Gastrointestinal system involvement in systemic lupus erythematosus. Lupus. 26:1127–38. DOI: 10.1177/0961203317707825. PMID: 28523968.

4. Ward MM. 1999; Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42:338–46. DOI: 10.1002/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U. PMID: 10025929.

5. Danchenko N, Satia JA, Anthony MS. 2006; Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 15:308–18. DOI: 10.1191/0961203306lu2305xx. PMID: 16761508.

6. Renau AI, Isenberg DA. 2012; Male versus female lupus: a comparison of ethnicity, clinical features, serology and outcome over a 30 year period. Lupus. 21:1041–8. DOI: 10.1177/0961203312444771. PMID: 22505605.

7. Yen EY, Singh RR. 2018; Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015. Arthritis Rheumatol. 70:1251–5. DOI: 10.1002/art.40512. PMID: 29671279. PMCID: PMC6105528.

8. Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. 2021; Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 60:207–16. DOI: 10.1093/rheumatology/keaa267. PMID: 32653901. PMCID: PMC8312724.

9. Lee YH, Choi SJ, Ji JD, Song GG. 2016; Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 25:727–34. DOI: 10.1177/0961203315627202. PMID: 26811368.

10. Ju JH, Yoon SH, Kang KY, Kim IJ, Kwok SK, Park SH, et al. 2014; Prevalence of systemic lupus erythematosus in South Korea: an administrative database study. J Epidemiol. 24:295–303. DOI: 10.2188/jea.JE20120204. PMID: 24857955. PMCID: PMC4074634.

11. Chung MK, Park JS, Lim H, Lee CH, Lee J. 2021; Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: a nationwide population-based study. Lupus. 30:674–9. DOI: 10.1177/0961203320984845. PMID: 33460342.

12. Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, et al. 2020; Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. Korean J Intern Med. 35:652–61. DOI: 10.3904/kjim.2018.303. PMID: 31212409. PMCID: PMC7214355.

13. Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. 2014; Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol Int. 34:909–17. DOI: 10.1007/s00296-013-2915-9. PMID: 24322455.

14. Kim H, Cho SK, Kim JW, Jung SY, Jang EJ, Bae SC, et al. 2020; An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin Arthritis Rheum. 50:526–33. DOI: 10.1016/j.semarthrit.2019.11.007. PMID: 31852583.

15. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. 2017; The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 56:1945–61. DOI: 10.1093/rheumatology/kex260. PMID: 28968809.

16. Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT. 2020; Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. Lupus. 29:15–26. DOI: 10.1177/0961203319888691. PMID: 31726936.

17. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. 2012; Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford). 51:721–9. DOI: 10.1093/rheumatology/ker370. PMID: 22179737.

18. Chiu YM, Lai CH. 2010; Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus. 19:1250–5. DOI: 10.1177/0961203310373780. PMID: 20647248.

19. Lewis MJ, Jawad AS. 2017; The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford). 56(suppl_1):i67–77. DOI: 10.1093/rheumatology/kew399. PMID: 27940583.

20. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. 2004; The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore). 83:1–17. DOI: 10.1097/01.md.0000104742.42401.e2. PMID: 14747764.

21. Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. 2016; The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 55:252–62. DOI: 10.1093/rheumatology/kev311. PMID: 26342222. PMCID: PMC4939728.

22. Parodis I, Tamirou F, Houssiau FA. 2020; Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 7:e000389. DOI: 10.1136/lupus-2020-000389. PMID: 32153796. PMCID: PMC7046967.

23. Kang JH, Park DJ, Lee KE, Lee JS, Choi YD, Lee SS. 2017; Comparison of clinical, serological, and prognostic differences among juvenile-, adult-, and late-onset lupus nephritis in Korean patients. Clin Rheumatol. 36:1289–95. DOI: 10.1007/s10067-017-3641-6. PMID: 28444577.

24. Chen YM, Lin CH, Chen HH, Chang SN, Hsieh TY, Hung WT, et al. 2014; Onset age affects mortality and renal outcome of female systemic lupus erythematosus patients: a nationwide population-based study in Taiwan. Rheumatology (Oxford). 53:180–5. DOI: 10.1093/rheumatology/ket330. PMID: 24136069.

25. Jeon H, Lee J, Ju JH, Kim WU, Park SH, Moon SJ, et al. 2022; Chronic kidney disease in Korean patients with lupus nephritis: over a 35-year period at a single center. Clin Rheumatol. 41:1665–74. DOI: 10.1007/s10067-021-06030-w. PMID: 35178647.

26. Yu KH, Kuo CF, Chou IJ, Chiou MJ, See LC. 2016; Risk of end-stage renal disease in systemic lupus erythematosus patients: a nationwide population-based study. Int J Rheum Dis. 19:1175–82. DOI: 10.1111/1756-185X.12828. PMID: 26864331.

27. Maningding E, Dall'Era M, Trupin L, Murphy LB, Yazdany J. 2020; Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the California Lupus Surveillance Project. Arthritis Care Res (Hoboken). 72:622–9. DOI: 10.1002/acr.23887. PMID: 31115180. PMCID: PMC6872905.

28. Adler M, Chambers S, Edwards C, Neild G, Isenberg D. 2006; An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford). 45:1144–7. DOI: 10.1093/rheumatology/kel039. PMID: 16527882.

29. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. 2012; Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 64:159–68. DOI: 10.1002/acr.20683. PMID: 22052624.

30. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. 2004; Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 31:2156–62. PMID: 15517627.

31. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. 2001; The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 57:496–500. DOI: 10.1212/WNL.57.3.496. PMID: 11502919.

32. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. 1992; The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol. 19:47–52. PMID: 1556699.

33. Pamuk ON, Raza AA, Hasni S. 2023; Jun. 21. Neuropsychiatric lupus in late and early onset systemic lupus erythematosus patients: a systematic review and meta-analysis. Rheumatology (Oxford). [Epub]. DOI: 10.1093/rheumatology/kead297. DOI: 10.1093/rheumatology/kead297. PMID: 37341643.

34. Ahn GY, Kim D, Won S, Song ST, Jeong HJ, Sohn IW, et al. 2018; Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 27:1338–47. DOI: 10.1177/0961203318772021. PMID: 29688144.

35. Meier AL, Bodmer NS, Wirth C, Bachmann LM, Ribi C, Pröbstel AK, et al. 2021; Neuro-psychiatric manifestations in patients with systemic lupus erythematosus: a systematic review and results from the Swiss lupus cohort study. Lupus. 30:1565–76. DOI: 10.1177/09612033211025636. PMID: 34152246. PMCID: PMC8489688.

36. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. 2003; Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 30:985–92. PMID: 12734893.

37. Hanly JG, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, et al. 2020; Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 79:356–62. DOI: 10.1136/annrheumdis-2019-216150. PMID: 31915121.

38. Quadrelli SA, Alvarez C, Arce SC, Paz L, Sarano J, Sobrino EM, et al. 2009; Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. 18:1053–60. DOI: 10.1177/0961203309106601. PMID: 19762378.

39. Segal AM, Calabrese LH, Ahmad M, Tubbs RR, White CS. 1985; The pulmonary manifestations of systemic lupus erythematosus. Semin Arthritis Rheum. 14:202–24. DOI: 10.1016/0049-0172(85)90040-X. PMID: 2934817.

40. Al-Adhoubi NK, Bystrom J. 2020; Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies. Lupus. 29:355–63. DOI: 10.1177/0961203320903798. PMID: 32036761. PMCID: PMC7436451.

41. Jiang M, Chen R, Zhao L, Zhang X. 2021; Risk factors for mortality of diffuse alveolar hemorrhage in systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Res Ther. 23:57. DOI: 10.1186/s13075-021-02435-9. PMID: 33593433. PMCID: PMC7885396.

42. Kazzaz NM, Coit P, Lewis EE, McCune WJ, Sawalha AH, Knight JS. 2015; Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival. Lupus Sci Med. 2:e000117. DOI: 10.1136/lupus-2015-000117. PMID: 26430514. PMCID: PMC4586940.

43. Chang MY, Fang JT, Chen YC, Huang CC. 2002; Diffuse alveolar hemorrhage in systemic lupus erythematosus: a single center retrospective study in Taiwan. Ren Fail. 24:791–802. DOI: 10.1081/JDI-120015681. PMID: 12472201.

44. Sun Y, Zhou C, Zhao J, Wang Q, Xu D, Zhang S, et al. 2020; Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. Lupus. 29:795–803. DOI: 10.1177/0961203320920715. PMID: 32321345.

45. Kwok SK, Moon SJ, Ju JH, Park KS, Kim WU, Cho CS, et al. 2011; Diffuse alveolar hemorrhage in systemic lupus erythematosus: risk factors and clinical outcome: results from affiliated hospitals of Catholic University of Korea. Lupus. 20:102–7. DOI: 10.1177/0961203310381511. PMID: 20956464.

46. Martínez-Martínez MU, Abud-Mendoza C. 2011; Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. Lupus. 20:568–74. DOI: 10.1177/0961203310392430. PMID: 21558137.

47. Kim D, Choi J, Cho SK, Choi CB, Kim TH, Jun JB, et al. 2017; Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 46:782–7. DOI: 10.1016/j.semarthrit.2016.09.004. PMID: 27745903.

48. Prabu A, Patel K, Yee CS, Nightingale P, Situnayake RD, Thickett DR, et al. 2009; Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford). 48:1506–11. DOI: 10.1093/rheumatology/kep203. PMID: 19671698.

49. Chen HA, Hsu TC, Yang SC, Weng CT, Wu CH, Sun CY, et al. 2019; Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. Arthritis Res Ther. 21:82. DOI: 10.1186/s13075-019-1868-0. PMID: 30917868. PMCID: PMC6438012.

50. Pérez-Peñate GM, Rúa-Figueroa I, Juliá-Serdá G, León-Marrero F, García-Quintana A, Ortega-Trujillo JR, et al. 2016; Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors. J Rheumatol. 43:323–9. DOI: 10.3899/jrheum.150451. PMID: 26669915.

51. Tselios K, Gladman DD, Urowitz MB. 2017; Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. Open Access Rheumatol. 9:1–9. DOI: 10.2147/OARRR.S123549. PMID: 28053559. PMCID: PMC5191623.

52. Li M, Wang Q, Zhao J, Li Z, Ye Z, Li C, et al. 2014; Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus. 23:1085–91. DOI: 10.1177/0961203314527366. PMID: 24651670.

53. Min HK, Lee JH, Jung SM, Lee J, Kang KY, Kwok SK, et al. 2015; Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival. Korean J Intern Med. 30:232–41. DOI: 10.3904/kjim.2015.30.2.232. PMID: 25750566. PMCID: PMC4351331.

54. Kim JS, Kim D, Joo YB, Won S, Lee J, Shin J, et al. 2018; Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients. Lupus. 27:1769–77. DOI: 10.1177/0961203318788163. PMID: 30028258.

55. Arnaud L, Tektonidou MG. 2020; Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford). 59(Suppl5):v29–38. DOI: 10.1093/rheumatology/keaa382. PMID: 33280012. PMCID: PMC7719040.

56. Björnådal L, Yin L, Granath F, Klareskog L, Ekbom A. 2004; Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol. 31:713–9. PMID: 15088296.

57. Guraieb-Chahín P, Cantú-Brito C, Soto-Mota A, Guerrero-Torres L, Flores-Silva F, Chiquete E, et al. 2020; Stroke in systemic lupus erythematosus: epidemiology, mechanism, and long-term outcome. Lupus. 29:437–45. DOI: 10.1177/0961203320908947. PMID: 32151182.

58. Tornvall P, Göransson A, Ekman J, Järnbert-Pettersson H. 2021; Myocardial infarction in systemic lupus erythematosus: incidence and coronary angiography findings. Angiology. 72:459–64. DOI: 10.1177/0003319720985337. PMID: 33412909. PMCID: PMC8044619.

59. Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, et al. 2014; Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 41:680–7. DOI: 10.3899/jrheum.130874. PMID: 24532834. PMCID: PMC3975689.

60. Barbhaiya M, Feldman CH, Chen SK, Guan H, Fischer MA, Everett BM, et al. 2020; Comparative risks of cardiovascular disease in patients with systemic lupus erythematosus, diabetes mellitus, and in general medicaid recipients. Arthritis Care Res (Hoboken). 72:1431–9. DOI: 10.1002/acr.24328. PMID: 32475049. PMCID: PMC7781242.

61. Bengtsson C, Ohman ML, Nived O, Rantapää Dahlqvist S. 2012; Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus. 21:452–9. DOI: 10.1177/0961203311425524. PMID: 22065097.

62. Chen SK, Barbhaiya M, Fischer MA, Guan H, Yoshida K, Feldman CH, et al. 2019; Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Semin Arthritis Rheum. 49:389–95. DOI: 10.1016/j.semarthrit.2019.06.005. PMID: 31280938. PMCID: PMC6918835.

63. Magder LS, Petri M. 2012; Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 176:708–19. DOI: 10.1093/aje/kws130. PMID: 23024137. PMCID: PMC3571250.

64. Lim SY, Bae EH, Han KD, Jung JH, Choi HS, Kim HY, et al. 2018; Systemic lupus erythematosus is a risk factor for cardiovascular disease: a nationwide, population-based study in Korea. Lupus. 27:2050–6. DOI: 10.1177/0961203318804883. PMID: 30282562.

65. Yafasova A, Fosbøl EL, Schou M, Baslund B, Faurschou M, Docherty KF, et al. 2021; Long-term cardiovascular outcomes in systemic lupus erythematosus. J Am Coll Cardiol. 77:1717–27. DOI: 10.1016/j.jacc.2021.02.029. PMID: 33832598.

66. Han JY, Kim HY, Jeon YN, Kang GE, Jung SY, Jang EJ, et al. 2022; Increased cardiovascular risk in patients with systemic lupus erythematosus: population-based cohort study in Korea. J Rheum Dis. 29 Suppl 1:116. DOI: 10.1136/annrheumdis-2023-eular.5912.

67. Han JY, Cho SK, Jeon Y, Kang G, Kim H, Jung SY, et al. 2023; Comparative cardiovascular risk in patients with older-onset systemic lupus erythematosus: a nationwide retrospective cohort study in Korea. Lupus Sci Med. 10(Suppl 1):A66–7. DOI: 10.1136/lupus-2023-KCR.94.

68. Hsu CY, Lin MS, Su YJ, Cheng TT, Lin YS, Chen YC, et al. 2017; Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 56:620–8. DOI: 10.1093/rheumatology/kew457. PMID: 28039419.

69. Chen YJ, Chang YT, Wang CB, Wu CY. 2010; Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 123:1150.e1–6. DOI: 10.1016/j.amjmed.2010.08.006. PMID: 21183006.

70. Han JY, Kim H, Jung SY, Jang EJ, Cho SK, Sung YK. 2021; Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea. Arthritis Res Ther. 23:270. DOI: 10.1186/s13075-021-02648-y. PMID: 34706772. PMCID: PMC8555049.

71. Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim CS, et al. 2019; Systemic lupus erythematosus is a risk factor for cancer: a nationwide population-based study in Korea. Lupus. 28:317–23. DOI: 10.1177/0961203319826672. PMID: 30712493.

72. Kang KY, Kim HO, Yoon HS, Lee J, Lee WC, Ko HJ, et al. 2010; Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol. 29:381–8. DOI: 10.1007/s10067-009-1332-7. PMID: 20041274.

73. Björnådal L, Löfström B, Yin L, Lundberg IE, Ekbom A. 2002; Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 31:66–71. DOI: 10.1080/03009740252937568. PMID: 12109649.

74. Westermann R, Zobbe K, Cordtz R, Haugaard JH, Dreyer L. 2021; Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: a Danish nationwide cohort study. Lupus. 30:752–61. DOI: 10.1177/0961203321990106. PMID: 33497306.

75. Dey D, Kenu E, Isenberg DA. 2013; Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study. Lupus. 22:919–27. DOI: 10.1177/0961203313497118. PMID: 23857987. PMCID: PMC4107831.

76. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. 2013; Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 42:130–5. DOI: 10.1016/j.jaut.2012.12.009. PMID: 23410586. PMCID: PMC3646904.

77. Song L, Wang Y, Zhang J, Song N, Xu X, Lu Y. 2018; The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis Res Ther. 20:270. DOI: 10.1186/s13075-018-1760-3. PMID: 30522515. PMCID: PMC6282326.

78. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, et al. 2004; Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol. 31:1763–7. PMID: 15338497.

79. Bashir S, Harris G, Denman MA, Blake DR, Winyard PG. 1993; Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis. 52:659–66. DOI: 10.1136/ard.52.9.659. PMID: 8239761. PMCID: PMC1005143.

80. Lin YJ, Wan L, Huang CM, Chen SY, Huang YC, Lai CH, et al. 2009; Polymorphisms in the DNA repair gene XRCC1 and associations with systemic lupus erythematosus risk in the Taiwanese Han Chinese population. Lupus. 18:1246–51. DOI: 10.1177/0961203309345777. PMID: 19880550.

81. Petri M, Genovese M. 1992; Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. J Rheumatol. 19:1559–65. PMID: 1464868.

82. Lee JW, Park DJ, Kang JH, Choi SE, Yim YR, Kim JE, et al. 2016; The rate of and risk factors for frequent hospitalization in systemic lupus erythematosus: results from the Korean lupus network registry. Lupus. 25:1412–9. DOI: 10.1177/0961203316640916. PMID: 27000153.

83. Koh JH, Park EK, Lee HN, Kim Y, Kim GT, Suh YS, et al. 2020; Clinical characteristics and survival of 413 patients with systemic lupus erythematosus in southeastern areas of South Korea: a multicenter retrospective cohort study. Int J Rheum Dis. 23:92–100. DOI: 10.1111/1756-185X.13761. PMID: 31802639.

84. Goldblatt F, Chambers S, Rahman A, Isenberg DA. 2009; Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 18:682–9. DOI: 10.1177/0961203308101019. PMID: 19502263.

85. Jung JY, Yoon D, Choi Y, Kim HA, Suh CH. 2019; Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Sci Rep. 9:9704. DOI: 10.1038/s41598-019-46039-5. PMID: 31273256. PMCID: PMC6609713.

86. Abe K, Ishikawa Y, Kita Y, Yajima N, Inoue E, Sada KE, et al. 2022; Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study. Arthritis Res Ther. 24:179. DOI: 10.1186/s13075-022-02869-9. PMID: 35902976. PMCID: PMC9330647.

87. Simard JF, Rossides M, Gunnarsson I, Svenungsson E, Arkema EV. 2021; Infection hospitalisation in systemic lupus in Sweden. Lupus Sci Med. 8:e000510. DOI: 10.1136/lupus-2021-000510. PMID: 34526357. PMCID: PMC8444249.

88. Rodziewicz M, Dyball S, Lunt M, McDonald S, Sutton E, Parker B, et al. 2023; Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study. Lancet Rheumatol. 5:e284–92.

89. Kang KY, Kwok SK, Ju JH, Park KS, Cho CS, Kim HY, et al. 2011; The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus. 20:989–97. DOI: 10.1177/0961203311402245. PMID: 21700655.

90. Chun BC, Bae SC. 2005; Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang lupus cohort in Seoul, Korea. Lupus. 14:635–8. DOI: 10.1191/0961203305lu2180xx. PMID: 16175938.

91. Gianfrancesco MA, Dall'Era M, Murphy LB, Helmick CG, Li J, Rush S, et al. 2021; Mortality among minority populations with systemic lupus erythematosus, including Asian and Hispanic/Latino persons - California, 2007-2017. MMWR Morb Mortal Wkly Rep. 70:236–9. DOI: 10.15585/mmwr.mm7007a2. PMID: 33600382. PMCID: PMC7891689.

92. Wang Z, Li M, Wang Y, Xu D, Wang Q, Zhang S, et al. 2018; Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China. Lupus. 27:864–9. DOI: 10.1177/0961203317751852. PMID: 29308727.

93. Lotfy Fayed H, Ibrahim Emara N. A Mohammed RH. 2022; Mortality and disease related comorbidities in systemic lupus erythematosus: data from an Egyptian cohort. Lupus. 31:628–36. DOI: 10.1177/09612033221081691. PMID: 35306918.